TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: need for further fat grafting
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nicotine-enhanced MMN amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction in prescription opioid overdose risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continued use of intervention techniques
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of stroke and cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dryness of the mouth
Endpoint domain: Adverse events/effects
Primary endpoint: phantom pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative sedation incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic lymphocytic leukaemia risk
Endpoint domain: Mortality/survival
Primary endpoint: pre‐procedural cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual‐like cramping
Endpoint domain: Adverse events/effects
Primary endpoint: vaginal spotting
Endpoint domain: Adverse events/effects
Primary endpoint: Transfusion or Hb less than or equal to 8.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time to opioid relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatic phenomena as presenting problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective effectiveness against influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive Affect Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major depressive disorder frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16-week weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hypoglycaemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Nocturnal hypoglycaemia events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in PSM total scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Depression Rating Scale‐Revised total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of medically attended injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean plasma [NO3‐]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet O2 consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet cytosolic [Ca++]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of POD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dye leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: I-PSS score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global quality of life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of vital bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage of residual graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in ESS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initiation time of forward steps under dual task conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initiation time of backward steps under dual task conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: assessors' ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesic advantage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events after cataract surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Additional intraocular surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IPV disclosure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum follicle size over 13 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: evidence of ovulation based on serum progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of abrupt improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent VTEs
Endpoint domain: Mortality/survival
Primary endpoint: Positive Pulfrich's pendulum test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of adverse microsubstaging variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of positive bacterial cultures at 18 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mortality data in COPD
Endpoint domain: Mortality/survival
Primary endpoint: VLDL‐apoC‐III concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fractional catabolic rate of VLDL‐apoC‐III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term compliance belief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Treatment Failure (TTTF)
Endpoint domain: Mortality/survival
Primary endpoint: plasma triglyceride (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: %fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biomarker-confirmed measure of viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dual-task cognitive performance (DTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual-task gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk impairment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental haemozoin deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexors and extensors strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maternal PRAQ‐R2 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total hemoglobin (HbT) responses to sad speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subjective grading of noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee function assessed from the Cincinnati Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short‐Form‐36 Bodily Pain sub score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duration of 'off' time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: PHDD at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in TSB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of contraceptive effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of reading the table
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: surgical site complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Amplitude of Glycemic Excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in diameter of stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: platelet microaggregation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma cGMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary cGMP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Request for bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in NIHSS scores of ≥2 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: papilla index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of secretions collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean dynamic compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall KS response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV viral load <50 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative size of the antrostomy area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DU recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of HAP by day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Delta of cortisolemia at 60 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pertussis response (PT) at 7 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-PRP geometric mean titer after 18-month booster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in the number of cases of ACL
Endpoint domain: Mortality/survival
Primary endpoint: Number of aphthous ulcers/month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days in pain/month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood and plasma Se concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Red cell GSH-Px activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uncorrected visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive stability within +/- 1.00 D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of best spectacle-corrected visual acuity
Endpoint domain: Adverse events/effects
Primary endpoint: Elevated PSA levels normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Errors in performing tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for surgical closure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: climacteric-like symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: prolonged postoperative urinary retention
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in American Urological Association symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: umbilical cord length index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of test to reference formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in TRQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reaching clinical significance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of self-help treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: single-leg triple hop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic postural stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Verbal numeric pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin fragment 1+2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibrinolytic factors (plasmin alpha 2‐plasmin inhibitor complex, D‐dimer, fibrinogen degradation products)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rate of nonsmoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric acid output inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to first solid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to passing of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: proportional hematoma growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequacy of thromboprophylaxis prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of overprescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient consent rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EC50 values for SEF95 suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in GBS Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: leg and whole-body lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma myostatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement time of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total laryngeal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate relief at week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ICU length of stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Postoperative myocardial function preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wound care skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensorimotor deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum total CPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour necrosis factor‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bone-specific alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wart diameter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retear rate for the repaired cuff tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of Motion (ROM) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Death or persistent hospitalization at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: unmet social support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: LH activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AURC(LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: QUICKY index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cumulative incidences of endometrial hyperplasia
Endpoint domain: Adverse events/effects
Primary endpoint: prevalences of vaginal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hydroperoxides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to therapies based on APA guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of insecticide-treated nets
Endpoint domain: Mortality/survival
Primary endpoint: Craving for d-methamphetamine
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive subjective measures of stimulation and mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: alcohol consumption on drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 10% reduction in sum of longest diameters (SLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical recurrence of sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of BMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final mitral valve area (MVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitral regurgitation (MR) > 2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous closure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean haemoglobin improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted cure rates (ACPRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumococcal resistance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: infant sum of skinfolds at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: need of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean difference in ACD at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of treadmill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morning ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HbA1c change at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of hypoglycemia at ≤70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BG variability (within-day and between-day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean SBS (Shear Bond Strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with vaccination schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better dietary patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: muscle latency times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CBF change in the hypothalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depth of cycloplegia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum HCO3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight and body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma BCAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in synovial lining volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation rate of benzodiazepine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in benzodiazepine usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of type 2 myocardial infarction (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hazard of cardiovascular death following type 2 MI
Endpoint domain: Mortality/survival
Primary endpoint: Increased frequency of recalled symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes